|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 November 2000, Vol. 96, No. 9, pp. 3147-3153
NEOPLASIA
Elevated soluble MUC1 levels and decreased
anti-MUC1 antibody levels in patients with
multiple myeloma
Steven P. Treon,
Peter Maimonis,
Deborah Bua,
Gloria Young,
Noopur Raje,
Joseph Mollick,
Dharminder Chauhan,
Yu-Tzu Tai,
Teru Hideshima,
Yoshihito Shima,
Jo Hilgers,
Silvia von
Mensdorff-Pouilly,
Andrew R. Belch,
Linda M. Pilarski, and
Kenneth C. Anderson
From the Department of Adult Oncology, Dana Farber
Cancer Institute; and Department of Medicine, Harvard Medical School,
Boston, MA; Bayer Diagnostics, Walpole, MA; Academic Hospital, Vrije
Universiteit, Amsterdam, The Netherlands; and Department of Medical
Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Soluble MUC1 (sMUC1) levels are elevated in many MUC1+
cancers. We and others have shown that MUC1 is expressed on multiple myeloma (MM) plasma cells and B cells. In this study, we measured sMUC1
levels in bone marrow (BM) plasma from 71 MM patients and 21 healthy
donors (HDs), and in peripheral blood (PB) plasma from 42 MM
patients and 13 HDs using an immunoassay that detects the CA27.29
epitope of MUC1. sMUC1 levels were found to be significantly greater
(mean 31.76 U/mL, range 5.69 to 142.48 U/mL) in MM patient BM plasma
versus HD BM plasma (mean 9.68 U/mL, range 0.65 to 39.83 U/mL)
(P < .001). Importantly, BM plasma sMUC1 levels were
related to tumor burden because sMUC1 levels were significantly higher for MM patients with active disease (34.62 U/mL, range 5.69 to 142.48 U/mL) versus MM patients with minimal residual disease (16.16 U/mL,
range 5.7 to 56.68 U/mL) (P = .0026). sMUC1 levels were
also elevated in the PB plasma of MM patients (32.79 U/mL, range 4.15 to 148.84 U/mL) versus HDs (18.47 U/mL, range 8.84 to 42.49)
(P = .0052). Lastly, circulating immunglobulin M (IgM) and IgG antibodies to MUC1 were measured in 114 MM patients and 31 HDs,
because natural antibodies to MUC1 have been detected in patients with
other MUC1-bearing malignancies. These studies demonstrated lower
levels of circulating IgM (P < .001) and IgG (P = .078) antibodies to MUC1 in MM patients compared
with HDs. Our data therefore show that in MM patients, sMUC1 levels are elevated and correlate with disease burden, whereas anti-MUC1 antibody
levels are decreased.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. B. Rubinstein, M. Karmely, R. Ziv, I. Benhar, O. Leitner, S. Baron, B.-Z. Katz, and D. H. Wreschner
MUC1/X Protein Immunization Enhances cDNA Immunization in Generating Anti-MUC1 {alpha}/{beta} Junction Antibodies that Target Malignant Cells
Cancer Res.,
December 1, 2006;
66(23):
11247 - 11253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Levitin, O. Stern, M. Weiss, C. Gil-Henn, R. Ziv, Z. Prokocimer, N. I. Smorodinsky, D. B. Rubinstein, and D. H. Wreschner
The MUC1 SEA Module Is a Self-cleaving Domain
J. Biol. Chem.,
September 30, 2005;
280(39):
33374 - 33386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al.
A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
Clin. Cancer Res.,
August 1, 2005;
11(15):
5504 - 5514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hayashi, T. Hideshima, M. Akiyama, N. Raje, P. Richardson, D. Chauhan, and K. C. Anderson
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes
Blood,
August 15, 2003;
102(4):
1435 - 1442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mileshkin, J. J. Biagi, P. Mitchell, C. Underhill, A. Grigg, R. Bell, J. McKendrick, P. Briggs, J. F. Seymour, K. Lillie, et al.
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Blood,
July 1, 2003;
102(1):
69 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles
Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma
Clin. Cancer Res.,
June 1, 2003;
9(6):
2213 - 2220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Thathiah, C. P. Blobel, and D. D. Carson
Tumor Necrosis Factor-alpha Converting Enzyme/ADAM 17 Mediates MUC1 Shedding
J. Biol. Chem.,
January 24, 2003;
278(5):
3386 - 3394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mitsiades, S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Blood,
August 1, 2001;
98(3):
795 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
